Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03322150 |
Recruitment Status :
Terminated
(The research was terminated because the recruitment of the study subjects was not smooth and the overseas training of the investigator was scheduled.)
First Posted : October 26, 2017
Last Update Posted : March 14, 2019
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Spinal Anesthesia | Drug: Atropine Drug: Glycopyrrolate | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 2 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Effect of Atropine or Glycopyrrolate on the Prevention of Bradycardia During Sedation Using Dexmedetomidine in Adult Patients Undergoing Lower Extremity Surgery Under Spinal Anesthesia |
Actual Study Start Date : | October 1, 2017 |
Actual Primary Completion Date : | August 1, 2018 |
Actual Study Completion Date : | August 1, 2018 |

Arm | Intervention/treatment |
---|---|
Active Comparator: Atropine group
Patients that receive atropine 0.01 mg/kg (max 0.5mg) before spinal anesthesia
|
Drug: Atropine
Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia |
Active Comparator: Glycopyrrolate group
Patients that receive glycopyrrolate 0.004mg/kg (max 0.2 mg) before spinal anesthesia
|
Drug: Glycopyrrolate
Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia |
- Pulse rate [ Time Frame: From 5 minutes before spinal anesthesia~end of surgery (Intraoperatively) ]measured as beats per minute, heart rate below 60 bpm or decrease of more than 30% from baseline is defined as bradycardia.
- blood pressure [ Time Frame: From 5 minutes before spinal anesthesia~end of surgery (Intraoperatively) ]measured as mmHg, mean blood pressure lower than 60 mmHg or decrease of more than 30% from baseline is defined as hypotension.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 20 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients 65 years or older undergoing total knee replacement surgery under spinal anesthesia.
- ASA class 1-3
Exclusion Criteria:
- Patients with coagulation abnormalities
- End organ diseases of liver, lung or kidney
- Severe aortic stenosis
- High degree AV block
- Heart failure
- Patients on MAO inhibitors
- History of seizures or epilepsy
- Glaucoma

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03322150
Korea, Republic of | |
Department of Anesthesiology and Pain Medicine, Anesthesia and Pain Research Institute, Yonsei University College of Medicine | |
Seoul, Korea, Republic of, 03722 |
Responsible Party: | Yonsei University |
ClinicalTrials.gov Identifier: | NCT03322150 |
Other Study ID Numbers: |
4-2013-0763 |
First Posted: | October 26, 2017 Key Record Dates |
Last Update Posted: | March 14, 2019 |
Last Verified: | March 2019 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Atropine glycopyrrolate bradycardia dexmedetomidine spinal anesthesia |
Bradycardia Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Atropine Glycopyrrolate Adjuvants, Anesthesia Anti-Arrhythmia Agents Bronchodilator Agents Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Anti-Asthmatic Agents Respiratory System Agents Mydriatics Parasympatholytics Muscarinic Antagonists Cholinergic Antagonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action |